IP Library Granted Patent US 7,599,746
Granted Patent B2
US 7,599,746 · App. 11/422,641 · Granted Oct 6, 2009

Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,599,746
App. No.
11/422,641
Granted
Oct 6, 2009
Kind
B2
Abstract

AC electric fields at certain frequencies and field strengths disrupt dividing cells, but leave undividing cells substantially unharmed. Since cancer cells divide much more often than normal cells, those AC fields have been shown to be effective at inhibiting tumor growth and shrinking tumors. Because certain body parts (e.g., the lungs and the liver) are at high risk for developing metastases in patients with some forms of cancer, treating those body parts with those AC fields can prevent metastases from growing in those body parts. This treatment may be used both after a metastasis has reached a detectable size and prophylactically (to prevent such metastases from ever reaching a detectable size in the first place). It may also be used to prevent cancer in people with a high probability of developing cancer (e.g., based on family history).

Claims (34)

1. A method of inhibiting the growth of metastases, the method comprising the step of:

applying an alternating electric field to a location in a living body, wherein the electric field has frequency and field strength characteristics such that the electric field disrupts at least some cells as they undergo division while leaving non-dividing cells in the location substantially unharmed, and wherein the electric field is applied during one or more intervals of time that are cumulatively sufficient to inhibit growth of metastases in the location.

2. The method of claim 1 , wherein the alternating electric field is applied to a location where metastases are likely to appear.

3. The method of claim 1 , wherein the alternating electric field is applied to at least one of a liver, a lung, a brain, and a bone.

4. The method of claim 1 , wherein the one or more intervals of time cumulatively comprise at least one week.

5. The method of claim 1 , wherein the one or more intervals of time cumulatively comprise at least one month.

6. The method of claim 1 , wherein the wherein the electric field has a frequency between about 100 kHz and about 300 kHz and a field strength between about 1 and about 10 V/cm.

7. A method of preventing metastases from growing, the method comprising the step of:

applying an alternating electric field to a location in a living body, wherein the electric field has frequency and field strength characteristics that provide the electric field with the ability to prevent metastases from growing while leaving non-dividing cells in the location substantially unharmed, and wherein the electric field is applied during one or more intervals of time that are cumulatively sufficient to prevent the metastases from growing in the location.

8. The method of claim 7 , wherein the alternating electric field is applied to a location where metastases are likely to appear.

9. The method of claim 7 , wherein the alternating electric field is applied to at least one of a liver, a lung, a brain, and a bone.

10. The method of claim 7 , wherein the one or more intervals of time cumulatively comprise at least one week.

11. The method of claim 7 , wherein the one or more intervals of time cumulatively comprise at least one month.

12. The method of claim 7 , wherein the wherein the electric field has a frequency between about 100 kHz and about 300 kHz and a field strength between about 1 and about 10 V/cm.

13. A method of inhibiting tumors from growing, the method comprising the steps of:

determining a location in a patient's body where tumors are likely to appear;

positioning electrodes with respect to the patient in positions that are selected to induce an alternating electric field at the location;

applying a AC voltage across the electrodes that induces an electric field at the location, wherein the AC voltage and the electrodes have characteristics that result in the induced electric field having frequency and amplitude characteristics that disrupt cells that undergo division while leaving non-dividing cells in the location substantially unharmed, and

wherein the electric field is applied for one or more periods of time that are cumulatively sufficient to inhibit growth of tumors in the location.

14. The method of claim 13 , wherein the alternating electric field is applied to a location where metastases are likely to appear.

15. The method of claim 13 , wherein the alternating electric field is applied to at least one of a liver, a lung, a brain, and a bone.

16. The method of claim 13 , wherein the one or more intervals of time cumulatively comprise at least one week.

17. The method of claim 13 , wherein the one or more intervals of time cumulatively comprise at least one month.

18. The method of claim 13 , wherein the wherein the electric field has a frequency between about 100 kHz and about 300 kHz and a field strength between about 1 and about 10 V/cm.

19. A method of preventing tumors from growing, the method comprising the step of:

applying an alternating electric field to a location in a living body, wherein the electric field has frequency and field strength characteristics such that the electric field disrupts a significant portion of cells as they undergo division while leaving non-dividing cells in the location substantially unharmed, and wherein the electric field is applied during one or more intervals of time that are cumulatively sufficient to disrupt a significant port ion of cells in the location that undergo division; and

repeating the applying step often enough to prevent tumors from growing in the location.

20. The method of claim 19 , wherein the alternating electric field is applied to a location where metastases are likely to appear.

21. The method of claim 19 , wherein the alternating electric field is applied to at least one of a liver, a lung, a brain, and a bone.

22. The method of claim 19 , wherein the one or more intervals of time cumulatively comprise at least one week.

23. The method of claim 19 , wherein the one or more intervals of time cumulatively comprise at least one month.

24. The method of claim 19 , wherein the wherein the electric field has a frequency between about 100 kHz and about 300 kHz and a field strength between about 1 and about 10 V/cm.

25. The method of claim 19 , wherein the repeating step comprises repeating the applying step at least once a year.

26. The method of claim 19 , wherein the repeating step comprises repeating the applying step at least once every six months.

Assignments (15)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →